AI assistant
ViroGates A/S — Director's Dealing 2022
Nov 17, 2022
8620_rns_2022-11-17_420d70b0-1442-452f-8e19-42a3c08417ff.pdf
Director's Dealing
Open in viewerOpens in your device viewer
ViroGates
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
17.11.2022 11:46:01 CET | ViroGates | Managers' transactions
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, this morning received notice of the following transactions by persons discharging managerial responsibilities according to MAR art. 19. The transaction notification form is listed below.
Skema, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til dem skal indberettes og offentliggøres
| 1. | Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne | ||
|---|---|---|---|
| a) | Navn | Patrik Dahlen | |
| 2. | Årsag til indberetningen | ||
| a) | Stilling/titel | Bestyrelsesformand | |
| b) | Første indberetning/æn- dring | Første indberetning | |
| 3. | Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplat- formen, auktionsholderen eller den auktionstilsynsførende | ||
| a) | Navn | ViroGates A/S | |
| b) | LEI-kode | 5493007TX8XS56RMZD94 | |
| 4. | Nærmere oplysninger om transaktionen/transaktionerne: gentages for i) hver type instrument, ii) hver type transaktion, iii) hver dato og iv) hvert sted, hvor der er udført transaktioner | ||
| a) | Beskrivelse af det finansielle instrument, instrumenttypen | ||
| Identifikationskode | Aktier | ||
| DK0061030574 | |||
| b) | Transaktionens art | Køb | |
| c) | Pris(er) og mængde(r) | Pris(er) | Mængde(r) |
| 40,93 | |||
| 42,5 | |||
| 44,79 | 2.902 | ||
| 83 | |||
| 2.300 | |||
| d) | Aggregerede oplysninger | ||
| Aggregeret mængde | |||
| Pris | 5.285 | ||
| DKK 225.322,90 | |||
| e) | Dato for transaktionen | 14-16/11-2022 | |
| f) | Sted for transaktionen | Nasdaq First North Growth Market Denmark (DSME) |
This announcement is also available on the company's website.
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: [email protected]
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönning
Tel. (+46) 40 200 250, email: [email protected]
About ViroGates
ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.
The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets. ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Disclosure regulation
Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.
Contacts
- Jakob Knudsen, CEO, +45 2226 1355, [email protected]
Attachments
- 20221117 FT indberetning ledende medarbejder PD.pdf